Immunofixation (IFE), Serum, Protein Electrophoresis (PE), Serum, and Quantitative Free κ and λ Light Chains (FLC) Plus Ratio
82784(3); 83883(x2); 84155; 84165; 86334
Free Light Chains, Quantitative, Serum
IFE, Serum and Protein Electrophoresis, Serum
Immunoelectrophoresis for Myeloma Proteins
Kappa Free Light Chains, Quantitative, Serum
Kappa:Lambda Free Light Chains Ratio, Quantitative, Serum
Lambda Free Light Chains, Quantitative, Serum
Light Chains, Free κ and Free λ, Quantitative, Serum
Detect and identify monoclonal gammopathy (M protein) found on serum protein electrophoresis; diagnose myeloma, macroglobulinemia of Waldenström; evaluate amyloidosis; evaluate lymphoproliferative disease (malignant lymphoma and others) and collagen disease in general; diagnose and characterize immune deficient and dysgammaglobulinemic states
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) recommend the use of serum free light chain assays in the initial diagnostic work-up of multiple myeloma and related disorders.
“Use of free light chain (FLC) assay along with SPEP and SIFE yields high sensitivity while screening for MM and related plasma cell disorders. Therefore, this assay is now included as a part of the initial diagnostic work-up in the NCCN Multiple Myeloma Guidelines.”
If screening for plasma cell dyscrasias, the International Myeloma Working Group recommends a screening panel consisting of serum free light chain assay, serum protein electrophoresis (SPEP), and serum immunofixation (IFE) to maximize sensitivity. (A 24-hour urine IFE can be added if AL amyloidosis is suspected.)
Red-top tube or gel-barrier tube
Patient should be fasting.
Sample should be allowed to clot and the serum separated as soon as possible to prevent hemolysis.
IFE: Refrigerated. PE and FLC: Room temperature